| Sep 9 |
Summit stock soars as lung cancer drug beats Merck’s Keytruda in late-stage trial
|
| Sep 9 |
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Sep 8 |
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
|
| Sep 8 |
Summit lung cancer drug shows ‘striking’ benefit over Keytruda
|
| Sep 2 |
Summit Therapeutics Insiders Added US$5.84m Of Stock To Their Holdings
|
| Aug 12 |
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
|
| Aug 11 |
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
|
| Aug 10 |
Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call Transcript
|
| Aug 6 |
Summit Therapeutics Non-GAAP EPS of -$0.05
|
| Aug 6 |
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
|
